Prostate - Chemotherapy in Metastatic Disease
Published: Thu Oct 13, 2011 Updated:Fri Oct 21, 2011
-
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study
S Niraul et al; Can Urol Assoc J 2011. http://dx.doi.org/10.5489/cuaj.11013
-
Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
R Pili et al, September 19, 2011, doi: 10.1200/JCO.2011.35.6295
-
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
JS de Bono et al, Ann Oncol. Sept 7 2011; doi:10.1093/annonc/mdr380
-
Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared with Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report from the ASCENT Investigators
TM Beer et al, JCO. Feb 20 2007; 25(6):669-74
-
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
DP Petrylak et al, NEJM. Oct 7 2004; 351(15):1513-20
-
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
IF Tannock et al, NEJM. Oct 7 2004; 351(15):1502-12
-
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
IF Tannock et al, JCO. Jun 1996; 14(6):1756-64
